Prostate cancer is among the most common cancers affecting men worldwide, and Abiraterone Acetate (Abiranamo 250mg) continues to be one of the most impactful treatments for metastatic castration-resistant disease. Unnati Pharmax supplies generic Abiranamo across Ottawa and Canada, and internationally across the Philippines, South Africa, Australia, and Singapore — helping patients access this life-extending medicine at a fraction of branded cost.
In Ottawa, private oncology patients and those facing provincial drug plan restrictions access Abiranamo at significantly reduced cost. In the Philippines, prostate cancer is the third most common male cancer and Abiraterone is often unaffordable at brand pricing — generic access through Unnati Pharmax changes this for Manila, Cebu, and Davao patients. In South Africa, where prostate cancer is the most commonly diagnosed cancer in men, Johannesburg and Cape Town oncology networks rely on affordable generic supply. In Sydney, Melbourne, Singapore, and beyond, self-funding patients save thousands monthly compared to private brand pricing.
Unnati Pharmax ships to all markets via DHL/FedEx with full WHO-GMP documentation. Visit medshopy.com or WhatsApp +91 82650 41513.
In Ottawa, private oncology patients and those facing provincial drug plan restrictions access Abiranamo at significantly reduced cost. In the Philippines, prostate cancer is the third most common male cancer and Abiraterone is often unaffordable at brand pricing — generic access through Unnati Pharmax changes this for Manila, Cebu, and Davao patients. In South Africa, where prostate cancer is the most commonly diagnosed cancer in men, Johannesburg and Cape Town oncology networks rely on affordable generic supply. In Sydney, Melbourne, Singapore, and beyond, self-funding patients save thousands monthly compared to private brand pricing.
Unnati Pharmax ships to all markets via DHL/FedEx with full WHO-GMP documentation. Visit medshopy.com or WhatsApp +91 82650 41513.
How does Abiranamo extend survival in prostate cancer — what is its mechanism?Abiraterone Acetate (Abiranamo) works by selectively and irreversibly inhibiting CYP17A1, an enzyme critical to androgen (testosterone) biosynthesis. While standard androgen deprivation therapy (ADT) reduces testicular testosterone production, it leaves adrenal gland androgen synthesis intact — and mCRPC tumours can also produce their own androgens locally. Abiranamo blocks CYP17A1 at all three sites: testes, adrenal glands, and within the tumour tissue itself, reducing testosterone to near-undetectable levels throughout the body. This comprehensive androgen blockade slows tumour growth significantly. Combined with prednisolone (which replaces the cortisol whose synthesis is also reduced by Abiranamo's mechanism), it extends median overall survival by over 4 months in previously treated patients and significantly longer in treatment-naive mCRPC.
